Key facts
- It has raised $3.3M; the latest was Seed Round ($3.3M) in Mar 2026.
- Notable investors include Credo Ventures, Kaya VC, Amino Collective, NAVEC Investment Management, Tilia Impact Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Theorema
- ·The full record, as it builds
Funding rounds
No funding rounds for Theorema are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Theorema
Developer of autonomous R&D agents intended to help biotech, pharmaceutical, chemicals, and advanced materials companies analyze experimental and literature data, optimize R&D workflows, and accelerate discovery cycles. The company's AI agents combine domain specific models, automated data extraction, and IP/reimbursement insights and have demonstrated top performance on industry benchmarks, enabling scientific and R&D teams to recover hidden R&D value, speed up hypothesis generation and validation, and improve the efficiency and ROI of complex research programs.
- Sector
- Information Technology
- HQ
- Prague, Czech Republic
- Website
- theorema.ai/
- Ownership
- Privately Held (backing)
Theorema doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Theorema shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Theorema in its N-PORT filings yet. We sweep new filings monthly.